Structural Hybridization as An Efficient Method for Novel Drug Candidates

Novel, highly effective, and safe treatment candidates against the wide range of disorders, such as cancer, viral infections, and microbial infections, may be discovered by structural hybridisation of pharmacologically active compounds that have already shown promise in animal studies. In an endeavour to resolve the constraints of several therapeutic treatments, strategies for drug-drug combinations have been devised to produce hybrid conjugates of various medications. Increased bioavailability, decreased toxicity, and prevention of drug resistances were the goals of developing hybrids, which are believed to enhance efficacy through likely multi-target interactions and targeted drug delivery to the site of action. In this review article, we focus on the logic of the hybrid design and the linker architecture in particular, highlighting the latest advances in the fast-expanding area of drug development. The linker architecture is critical to the overall success of a hybrid medication.